Sanofi launches its new global employee share ownership plan
08 June 2021 - 2:00AM
Sanofi launches its new global employee share ownership plan
|
Sanofi launches its new global employee share ownership
plan PARIS
- June 7,
2021 - Sanofi today launches
Action 2021, its global employee share ownership plan, open to
92,000 employees in 73 countries. The program, similar to programs
carried out since 2013, clearly demonstrates the ongoing commitment
of Sanofi and its Board of Directors to involve all employees,
across all its territories, in the future development and results
of the company. "The record level of employee participation in
last year’s share plan demonstrated our employee’s commitment to
the company and our long-term strategy and growth. With the
continued support of the Board of Directors, we want our employees
to have these opportunities to be increasingly involved in Sanofi's
success by sharing in its performance," said Paul Hudson, Chief
Executive Officer of Sanofi. As of today, the shares will be
offered at a subscription price of 69,38€, which is equal to a 20%
discount off the average of the 20 opening prices of Sanofi shares
from May 6 to June 2, 2021. In addition, for every five shares
subscribed, employees will be able to receive one free share (up to
a maximum of four free shares per employee). And finally, each
employee will be able to purchase up to 1,500 Sanofi shares within
the legal limit of a maximum payment amount that does not exceed
25% of their gross annual salary, minus any voluntary deductions
already made under employee savings schemes (Group Savings Plan
and/or Group Retirement Savings Plan) during the year 2021. In
2020, the employee share ownership plan, open to around 90,000
employees in 72 countries, saw its overall uptake rate exceed 36%.
More than 33,000 Sanofi employees chose to invest in the company.
Today, nearly 90,000 current or former employees of the company are
direct or indirect shareholders of Sanofi, and hold approximately
2.8% of its capital. Detailed conditionsAn eligibility
condition of three months employment by the closing date of the
offer period will apply. Eligible staff will be able to subscribe
shares from 7 June 2021 (inclusive) to 25 June 2021 (inclusive).
The issue is expected to be completed and the delivery of the
securities carried out by the end of July 2021.The maximum number
of Sanofi shares that may be issued under this offer is 6,294,858
shares (corresponding to a maximum capital increase of €12,589,717
at nominal value, being 0.5% of share capital) The new shares,
including the matching shares (the "Shares"), will be subscribed
(or delivered) either directly or through the intermediary of
employee mutual funds ("FCPE"), depending on the regulations and/or
tax regime applicable in the various countries of residence of
those eligible for the capital increase. The Shares will be
fully fungible with the existing ordinary shares comprising the
share capital of Sanofi and will acquire dividend rights as from 1
January 2021.The voting rights attached to the subscribed Shares
will be exercised directly by the employees. Those taking up this
offer will be required to hold the Shares or the corresponding FCPE
units for a period of approximately five years, i.e. until 31 May
2026, except upon the occurrence of an early release event provided
for under Article R. 3324-22 of the French Labour Code and
authorized in the subscriber's country. Admission of the Shares to
trading on the Euronext Paris market (ISIN Code: FR0000120578 ) on
the same line as the existing shares will be requested as soon as
possible after the completion of the capital increase.This press
release does not constitute an offer to sell or a solicitation to
buy Sanofi shares. The offer of Sanofi shares reserved for
employees will only be made in countries where such an offer has
been registered with or notified to the competent local authorities
and/or following the approval of a prospectus by the competent
local authorities, or in consideration of an exemption from the
requirement to prepare a prospectus or to register or notify of the
offer, where such procedure is required.More generally, the offer
will only be made in countries where all required registration
and/or notification procedures have been carried out, approvals
obtained, and procedures for consulting or informing employee
representatives followed.This press release is not intended for and
should not be copied to or distributed in countries where such a
prospectus has not been approved or such exemption is not available
or where all necessary registration, notification, consultation
and/or information procedures have not been completed or
authorisations obtained. This relates in particular to Cameroon,
Japan and the Philippines, where to date formalities are still
pending with the authorities but could also relate to other
countries. This press release is prepared in accordance
with the exemption from publication of a prospectus under Article 1
4°i) and 5°h) of the Prospectus Regulation (EU) 2017/1129. It
constitutes the document required to meet the conditions for
exemption from publication of a prospectus as defined by the
Prospectus Regulation. |
|
About Sanofi Sanofi is dedicated to
supporting people through their health challenges. We are a global
biopharmaceutical company focused on human health. We prevent
illness with vaccines, provide innovative treatments to fight pain
and ease suffering. We stand by the few who suffer from rare
diseases and the millions with long-term chronic
conditions. With more than 100,000 people in 100 countries,
Sanofi is transforming scientific innovation into healthcare
solutions around the globe. Sanofi, Empowering Life |
|
Media Relations ContactsAshleigh KossTel: +1 (908)
205-2572Ashleigh.Koss@sanofi.com Sandrine GuendoulTel.: +33
(0)6 25 09 14 25MR@sanofi.com Nicolas KressmannTel.: +1 (732)
532-5318Nicolas.Kressmann@sanofi.com |
Investor Relations Contacts ParisEva
Schaefer-JansenArnaud DelepineNathalie Pham Investor
Relations Contacts North AmericaFelix LauscherFara
BerkowitzSuzanne Greco IR main line:Tel.: +33 (0)1 53 77 45
45investor.relations@sanofi.com |
Sanofi (EU:SAN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sanofi (EU:SAN)
Historical Stock Chart
From Apr 2023 to Apr 2024
